NASDAQ:ACER - Acer Therapeutics Stock Price, Forecast & News

Acer Therapeutics trades on the NASDAQ under the ticker symbol "ACER."

Acer Therapeutics Inc (NASDAQ:ACER) released its quarterly earnings data on Wednesday, November, 13th. The biopharmaceutical company reported ($0.52) earnings per share for the quarter, topping analysts' consensus estimates of ($0.57) by $0.05. View Acer Therapeutics' Earnings History.

Acer Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Acer Therapeutics.

5 equities research analysts have issued 1 year target prices for Acer Therapeutics' stock. Their forecasts range from $9.00 to $48.00. On average, they anticipate Acer Therapeutics' stock price to reach $22.33 in the next year. This suggests a possible upside of 332.8% from the stock's current price. View Analyst Price Targets for Acer Therapeutics.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acer Therapeutics in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Acer Therapeutics.

Media coverage about ACER stock has been trending very negative this week, according to InfoTrie. The research firm identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Acer Therapeutics earned a news impact score of -3.6 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Acer Therapeutics.

Acer Therapeutics saw a drop in short interest during the month of January. As of January 15th, there was short interest totalling 442,900 shares, a drop of 8.8% from the December 31st total of 485,900 shares. Based on an average trading volume of 50,200 shares, the short-interest ratio is currently 8.8 days. Approximately 9.1% of the company's shares are short sold. View Acer Therapeutics' Current Options Chain.

Some companies that are related to Acer Therapeutics include Aeglea Bio Therapeutics (AGLE), Arcturus Therapeutics (ARCT), MediciNova (MNOV), LifeVantage (LFVN), Theratechnologies (THERF), Agile Therapeutics (AGRX), Cerecor (CERC), Arbutus Biopharma (ABUS), Affimed (AFMD), Theratechnologies (THTX), Abeona Therapeutics (ABEO), Kezar Life Sciences (KZR), Nature's Sunshine Products (NATR), Athersys (ATHX) and Five Prime Therapeutics (FPRX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Acer Therapeutics investors own include Sarepta Therapeutics (SRPT), NVIDIA (NVDA), Synergy Pharmaceuticals (SGYP), NovaBay Pharmaceuticals (NBY), Advanced Micro Devices (AMD), Amarin (AMRN), Novavax (NVAX), Arena Pharmaceuticals (ARNA), Anavex Life Sciences (AVXL) and Exelixis (EXEL).

Acer Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include State Street Corp (1.10%), Barclays PLC (0.97%), J. Goldman & Co LP (0.73%), Goldman Sachs Group Inc. (0.51%), Bank of Montreal Can (0.14%) and CWS Financial Advisors LLC (0.10%). Company insiders that own Acer Therapeutics stock include Life Science Ventures Vii Tvm and Steve Aselage. View Institutional Ownership Trends for Acer Therapeutics.

ACER stock was sold by a variety of institutional investors in the last quarter, including J. Goldman & Co LP, Goldman Sachs Group Inc., State Street Corp and Bank of Montreal Can. View Insider Buying and Selling for Acer Therapeutics.

ACER stock was purchased by a variety of institutional investors in the last quarter, including CWS Financial Advisors LLC, UBS Group AG and Barclays PLC. Company insiders that have bought Acer Therapeutics stock in the last two years include Life Science Ventures Vii Tvm and Steve Aselage. View Insider Buying and Selling for Acer Therapeutics.

Shares of ACER can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ACER stock can currently be purchased for approximately $5.16.

Acer Therapeutics has a market capitalization of $52.12 million. The biopharmaceutical company earns $-21,280,000.00 in net income (profit) each year or ($2.49) on an earnings per share basis. Acer Therapeutics employs 23 workers across the globe.View Additional Information About Acer Therapeutics.

The official website for Acer Therapeutics is http://www.acertx.com/.

Acer Therapeutics' mailing address is 300 WASHINGTON STREET SUITE 351, NEWTON MA, 02458. The biopharmaceutical company can be reached via phone at 844-902-6100 or via email at [email protected]